He spends his days where plant chemistry, machine learning and venture capital collide - and where mental-health medicines either move forward or stall.
At Sensorium Therapeutics, the science gets the headlines - a platform called SensAI that sifts more than 50 million curated relationships across biology, pharmacology and clinical outcomes, looking for the neuroactive patterns nature spent millennia perfecting. Evan Gibson does the other half of the work. As Chief Business Officer, he is the person who translates that science into deals, partnerships and a path to patients.
Sensorium is small on paper - roughly 27 people on Wareham Street in Boston's biotech-dense South End - and ambitious in practice: a clinical-stage company building brain and mental-health treatments that are, in its own words, derived from nature, mechanistically driven and clinically precise. Gibson's job is to make sure the molecules find money, momentum and a market.
He is not a bench scientist. He is the connective tissue between a lab full of chemistry and the capital, collaborators and corporate strategy that decide whether a promising anxiety compound becomes a real treatment or a paper that nobody reads.
"Derived from nature, mechanistically driven, clinically precise."
Most operators chase the hot therapeutic area of the moment. Gibson kept choosing the same hard one: the central nervous system. His resume reads like a tour of neuroscience and therapeutics startups - a competitive-intelligence role at Vir Biotechnology, work across Neumora (precision neuroscience medicines), Tempero Bio (substance-use disorders) and Junevity (cell-reset and longevity), plus a stretch as a Chief Business Officer inside the Aditum Bio venture ecosystem co-founded by former Novartis leaders.
The pattern is the point. While the company names change, the work rhymes: take early science that is genuinely novel, and build the business case that gets it funded and moving. It is unglamorous, repeatable, and exactly the skill a small biotech needs most.
The foundation underneath all of it is a Wharton MBA in Health Care Management - the degree that sits at the seam between medicine and money, which happens to be precisely where Gibson works.
Clinical-stage biotech using the SensAI platform to engineer nature-inspired CNS medicines. Gibson runs business development and corporate strategy.
The asset-centric biotech builder co-founded by ex-Novartis leaders Joe Jimenez and Mark Fishman, where Gibson served as a Chief Business Officer.
Clinical-stage company developing treatments for substance-use and related disorders - an Aditum portfolio company.
Precision neuroscience medicines - part of Gibson's long run through brain-focused biotech.
Cell-reset and longevity therapeutics, another stop on a career spent close to the frontier of biology.
A competitive-intelligence role - the kind of early seat that teaches you to read an entire industry, not just one company.
Company affiliations reflect publicly listed professional history. Roles and dates are summarized; not all are independently confirmed.
Sensorium was built by an unusually serious bench of scientists: Jacob Hooker, a Harvard Medical School professor and the company's CEO; Stephen Haggarty, a Harvard neuroscientist; and Jerrold Rosenbaum, chair emeritus of psychiatry at Massachusetts General Hospital. The pedigree is Boston-and-Harvard to the core.
In November 2022 the company closed a $30 million Series A, led by Santé Ventures and Route 66 Ventures with a roster of life-science and psychedelic-adjacent investors. The money funds a simple, audacious idea: that nature already solved much of neuropharmacology, and the job now is to read its answers with chemistry, neuroscience and machine learning.
That is the table Gibson sits at - a small company with big science, a real balance sheet, and a need for someone whose entire craft is turning all of it into deals.
The next mental-health breakthrough starts where nature meets machine learning.